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S U M M A R Y
A 68-year-old male underwent a right hepatectomy, resection of the biliary convergence, and a left
hepatic jejunostomy for a Klatskin tumour. The postoperative course was complicated by biliary
abscesses with relapsing bloodstream infections due to Klebsiella pneumoniae carbapenemase (KPC)-
producing Klebsiella pneumoniae (KPC-Kp). A 2-week course of combination antibiotic therapy failed to
provide source control and the bacteraemia relapsed. Success was obtained with a regimen of tigecycline
100 mg daily for 2 months, followed by tigecycline 50 mg daily for 6 months, then 50 mg every 48 h for
3 months. No side effects were reported.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Infections due to Klebsiella pneumoniae carbapenemase (KPC)-
producing Klebsiella pneumoniae (KPC-Kp) have spread rapidly
worldwide and are increasingly reported both in hospitals and
long-term care facilities.1 A higher mortality rate has been
observed (from 42% to 69%) in comparison to patients infected
with antibiotic-susceptible K. pneumoniae.2–4
The case of a patient with a KPC-Kp bloodstream infection (BSI)
occurring after major hepatectomy, which was treated successfully
with an unconventional strategy of antibiotic therapy, is reported
below.
2. Case report
A 68-year-old male underwent a right hepatectomy, resection
of the biliary convergence, and a left hepatic jejunostomy for a
Klatskin tumour in April 2013. The postoperative course was
complicated by KPC-Kp bacteraemia. KPC-Kp was also isolated
from biliary drainage and a rectal swab. The blood strain was§ Study supported by ARPA Foundation, www.fondazionearpa.it.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).susceptible to colistin (minimum inhibitory concentration (MIC)
0.38 mg/l), intermediate to tigecycline (MIC 2 mg/l), and resistant
to all other tested antibiotics including ertapenem, meropenem,
imipenem, gentamicin, fosfomycin, and trimethoprim/sulfameth-
oxazole. The patient received intravenous (IV) therapy with double
carbapenem (ertapenem 1 g daily plus imipenem/cilastatin 1 g
three times daily administered 4 h after a loading dose of 1 g),
combined with colistin 4.5 MU twice daily after a loading dose of
9 MU and tigecycline 100 mg twice daily after a loading dose of
200 mg. Blood cultures became negative after 24 h. The sepsis
symptoms resolved progressively and the patient was discharged
after 2 weeks of treatment.
Ten days later the patient was readmitted with fever, and a new
episode of BSI due to KPC-Kp with a similar antibiotic susceptibility
proﬁle was documented. Micro-abscesses along the intrahepatic
bile ducts were seen on ultrasonography.
The patient received IV therapy with colistin 4.5 MU twice daily
after a loading dose of 9 MU, rifampicin 600 mg, and tigecycline
100 mg twice daily after a loading dose of 200 mg. Again, the
resolution of symptoms, normalization of altered laboratory data,
and clearance of the KPC-Kp from the blood were obtained after
2 weeks and the patient was discharged.
In the following weeks the patient suffered from intermittent
episodes of fever and he was admitted to the Infectious Diseases
Unit. KPC-Kp was again isolated from the blood. He was treatedciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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administered 4 h after a loading dose of 2 g, colistin 4.5 MU twice
daily after a loading dose of 9 MU, and tigecycline 100 mg twice
daily after a loading dose of 200 mg, with an immediate clinical
response. After 4 days the colistin was interrupted due to acute
renal failure and cutaneous paresthesias.
After 2 weeks of treatment, 8 days after the resolution of fever,
the patient was discharged home with unconventional treatment
consisting of once-daily tigecycline 100 mg for 2 months then
50 mg for 6 months and 50 mg every 48 h for 3 months. No side
effects were reported. Six months after the end of treatment the
patient was free of clinical, laboratory, and radiological signs of
infection.
3. Discussion
Although the treatment of KPC-Kp infection is not well
standardized, some clinical evidence supports the beneﬁt of
high-dose, combination antibiotic therapy. Combination therapy
has been associated with signiﬁcantly higher survival rates in
comparison with monotherapy in patients with KPC-Kp BSIs, and
tigecycline plus colistin and meropenem has been shown to be the
most effective treatment.5 Sbrana et al. reported that a carbape-
nem-sparing regimen of high-dose tigecycline combined with
colistin or gentamicin was effective in the treatment of polytrauma
intensive care unit patients without comorbidities.6 Di Carlo et al.
reported tigecycline in combination with colistin to be more
effective at a higher dose in the treatment of postoperative
abdominal infections.7 The combination of two carbapenems has
been reported to be synergistic in vitro and effective in vivo,
probably due to the inhibition of the carbapenemase exerted by
ertapenem.8 In vitro, the addition of rifampicin has been proven to
signiﬁcantly reduce the colistin MIC against KPC-Kp.9 However,
these combination regimens require prolonged therapy with
multiple daily IV infusions and are potentially toxic.
In our patient a 2-week course of combination antibiotics was
able to control the bacteraemia, but failed to cure the biliary tract
infection that was the source of recurrences. Source control was
otherwise obtained with a prolonged, low-dose regimen of
tigecycline.
Tigecycline is licensed for complicated intra-abdominal infec-
tions and is eliminated mainly through the bile as unchanged drug.
After a 100-mg dose, tissue penetration, expressed as the ratio of
the area under the concentration–time curve from pre-dose to 24 h
post-dose (AUC0–24) in tissue or body ﬂuid to serum, was 537 for
the bile and 23 for the gallbladder; the concentration in the bile
after 24 h was 55.8 mg/l, far above the MIC of Enterobacteriaceae,
including the majority of KPC-Kp isolates.10 In fact, He et al.
recently studied the susceptibility to tigecycline of a collection of
215 KPC-Kp isolates: the great majority had a MIC of 1 or 2 mg/l,
however resistant isolates had a MIC not higher than 8 mg/l.11
Based on this pharmacokinetic proﬁle, it was hypothesized that
after resolution of the bacteraemia with combination therapy, the
prolonged administration of tigecycline at a lower dose might still
have ensured adequate concentrations in the biliary ducts.
Although serious adverse events during treatment with
tigecycline are quite rare, mild side effects, mainly nausea and
vomiting, are common and dose-related.12 A higher dilution, a
more prolonged infusion, food, and anti-emetics can only partiallyalleviate them. Nausea usually occurs in the ﬁrst 1–2 days of
treatment and is transient in most patients, but a very prolonged
treatment increases the risk of side effects overall. A reduced
frequency of administration, as in the case described here, might
improve tolerability.
The selection of resistance due to sub-standard doses is another
risk. However, studies on Escherichia coli suggest that reduced
susceptibility to tigecycline, mainly due to the expression of efﬂux
pumps, is probably related to ﬁtness costs, limiting the develop-
ment of high-level resistance and the spread of less susceptible
strains.13
Although generally regarded as a bacteriostatic agent, tigecy-
cline has a time-dependent bactericidal activity and a prolonged
post-antibiotic effect, as demonstrated particularly against Staph-
ylococcus aureus in animal models.14 Therefore, we can assume that
a prolonged treatment, as in the case described here, might
increase its efﬁcacy.
The case presented suggests that tigecycline might be effective
and safe as a suppressive treatment following initial adequate
induction therapy in the setting of biliary infections due to KPC-Kp.
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